Emerging genomic and diagnostic technologies seek to improve early detection and monitoring of cancers. Personalis and Tempus AI expanded their collaboration to include colorectal cancer, enhancing access to the ultra-sensitive NeXT Personal minimal residual disease assay. University of Chicago spinout OrisDx is preparing a saliva-based, next-generation sequencing test for early oral cancer detection, aiming to provide noninvasive screening in dental offices. Caris Life Sciences reported supportive data for its platform in cancer detection and monitoring, advancing towards commercial launch. These developments herald a shift toward more precise, accessible cancer diagnostics.